Sera Prognostics, Inc. (SERA) SEC filings

SERANasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30

$1.98+0.04 (+2.06%)

Close on Nov 12, 2026Market cap $78.11MP/E –Yield –

SEC filings

40 of Sera Prognostics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 19, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Jun 25, 2026	Jun 30, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 4, 2026	SEC EDGAR
Current report	8-K	May 26, 2026	Jun 1, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 6, 2026	SEC EDGAR
Current report	8-K	May 6, 2026	May 6, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 23, 2026	Apr 24, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 18, 2026	SEC EDGAR
Current report	8-K	Mar 18, 2026	Mar 18, 2026	SEC EDGAR
Current report	8-K	Jan 8, 2026	Jan 8, 2026	SEC EDGAR
Current report	8-K	Jan 7, 2026	Jan 7, 2026	SEC EDGAR
Current report	8-K	Nov 24, 2025	Nov 24, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Sep 5, 2025	Sep 5, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Aug 6, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Jun 5, 2025	Jun 5, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 7, 2025	SEC EDGAR
Current report	8-K	May 7, 2025	May 7, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2025	Apr 23, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 19, 2025	SEC EDGAR
Current report	8-K	Mar 19, 2025	Mar 19, 2025	SEC EDGAR
Current report	8-K	Feb 10, 2025	Feb 12, 2025	SEC EDGAR
Current report	8-K	Feb 10, 2025	Feb 10, 2025	SEC EDGAR
Current report	8-K	Jan 31, 2025	Jan 31, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 13, 2025	SEC EDGAR
Current report	8-K	Jan 6, 2025	Jan 7, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Nov 6, 2024	Nov 6, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 7, 2024	SEC EDGAR
Current report	8-K	Aug 7, 2024	Aug 7, 2024	SEC EDGAR
Current report	8-K	Jun 6, 2024	Jun 6, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Sera Prognostics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SERA.

Compare: SERA vs ADVB · SERA vs ACON · SERA vs YDES · SERA vs AWHL · SERA vs BGLC

Revenue growth1.1% · median -10.6%

Gross margin-86.5% · median 29.1%

Operating margin-38755.2% · median -4059.4%

Net margin-34866.7% · median -5885.3%

Company	Revenue	Growth
BGLC	$3.13M	-67.3%
AWHL	$170.00K	–
ACON	$98.56K	+46.0%
SERA	$96.00K	+1.1%
ADVB	–	–
YDES	–	–

Company

Next earnings (est.): Mar 17, 2027, after close
Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Held by institutions: 43.2%
Auditor: Ernst & Young LLP
SEC CIK: 1534969

Advertisement
300 × 250

See a number that looks wrong?